Hyperuricemia and Left Ventricular Diastolic Function

Associations and Plausibility Among Left Ventricle Diastolic Function, Serum Uric Acid and Inflammatory Biomarkers in Individuals With Cardiometabolic Risks - A Prospective Observational Study

Status

Terminated

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03495999

Enrollment

Registered

2018-04-12

Start date

2017-08-01

Completion date

2018-04-03

Last updated

2018-04-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hyperuricemia, Left Ventricular Diastolic Dysfunction, Metabolic Syndrome

Keywords

Hyperuricemia, Metabolic syndrome, Left ventricular diastolic dysfunction, Inflammation

Brief summary

Metabolic syndrome and hyperuricemia were both associated with inflammation, leading to diversities of cardiovascular disease such as left ventricular diastolic dysfunction, but the relationship among these entities remained unclear. The aim of the present study focuses on the association among hyperuricemia, diastolic dysfunction and inflammatory biomarkers in apparently healthy individuals with metabolic syndrome

Detailed description

Apparently healthy individuals with metabolic syndrome were prospectively and consecutively enrolled since August 2017. Blood samples were obtained after participants are fasting for at least 12 hours, including serum uric acid, high-sensitivity C-reactive protein, high-sensitivity interleukin-6, tumor necrotizing factor alpha, fasting glucose, glycosylated hemoglobin, insulin, lipid profile, creatinine, alanine aminotransferase, sodium, potassium, and calcium. All echocardiographic parameters were measured in accordance with the American Society of Echocardiography guidelines.

Interventions

DIAGNOSTIC_TESThyperuricemia

serum uric acid of 7mg/dl or more in men or 6mg/dl or more in women

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

20 Years to 75 Years

Inclusion criteria

1. Age between 20 to 75 years 2. Metabolic syndrome

Exclusion criteria

1. Left ventricular ejection fraction \<40% 2. Severe valvular heart disease 3. Significant structure heart diseases such as hypertrophic, dilated, infiltrative or restrictive cardiomyopathy, or congenital heart disease 4. Persistent or chronic atrial fibrillation 5. Status post cardiac surgery, including coronary artery bypass surgery of valve intervention 6. Status post intra-cardiac device implantation 7. Chronic obstructive pulmonary disease 8. Severe anemia 9. An obvious systemic disease that interferes left ventricular diastolic dysfunction such as acute coronary syndrome

Design outcomes

Primary

Measure	Time frame	Description
Left ventricle diastolic dysfunction with elevated left atrial pressure	1 day	The contemporary definition of left ventricular diastolic dysfunction with elevated left atrial pressure is mainly \>50% positive of the following criteria: (1) average E/e' ≥14 (2) left atrial volume index \>34 ml/m2 (3) tricuspid regurgitation velocity \>2.8 m/s

Secondary

Measure	Time frame	Description
high-sensitivity C-reactive protein	1 week	determined by Latex enhanced immunoturbidimetric，ADVIA 1800，ADVIA Chemistry XPT，Dimension RXL，SIEMENS，AU 640，Beckman Coulter
high-sensitivity interleukin-6	1 month	determined by elisa enzyme-linked immunosorbent assay, R & D system
tumor necrotizing factor alpha	1 month	determined by elisa enzyme-linked immunosorbent assay

Countries

Taiwan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026